1. Home
  2. CNSP
  3. CNSP News

Latest CNS Pharmaceuticals Inc. (CNSP) News on June 29, 2025

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
CNSP

ACCESS Newswire

5 days ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
CNSP

ACCESS Newswire

24 days ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNSP

ACCESS Newswire

a month ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNSP

ACCESS Newswire

2 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNSP

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

CNSP

MT Newswires

2 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
CNSP

ACCESS Newswire

2 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year
CNSP

TipRanks

3 months ago

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNSP

ACCESS Newswire

3 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven?
CNSP

Simply Wall St.

3 months ago

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven?

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNSP

ACCESS Newswire

3 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
CNSP

ACCESS Newswire

4 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNSP

ACCESS Newswire

4 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNSP

MT Newswires

4 months ago

CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
CNSP

ACCESS Newswire

4 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split
CNSP

ACCESS Newswire

4 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
CNSP

ACCESS Newswire

4 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
CNSP

ACCESS Newswire

5 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
CNSP

ACCESSWIRE

7 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNSP

ACCESSWIRE

7 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
CNSP

ACCESSWIRE

7 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
CNSP

ACCESSWIRE

7 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
CNSP

ACCESSWIRE

8 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNSP

MT Newswires

8 months ago

CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
CNSP

ACCESSWIRE

8 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CNSP

ACCESSWIRE

8 months ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
CNSP

ACCESSWIRE

9 months ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
CNSP

ACCESSWIRE

9 months ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
CNSP

ACCESSWIRE

9 months ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
CNSP

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CNSP

ACCESSWIRE

10 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
CNSP

GlobeNewswire

10 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
CNSP

ACCESSWIRE

10 months ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
CNSP

ACCESSWIRE

10 months ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
CNSP

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNSP

MT Newswires

a year ago

CNS Pharmaceuticals Files Prospectus for Sale of Up to 2.4 Million Shares by Stockholders

CNSP

MT Newswires

a year ago

CNS Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule

CNSP

MT Newswires

a year ago

CNS Pharmaceuticals Prices Direct Offering; Shares Rise

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNSP

MT Newswires

a year ago

Top Midday Decliners

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNSP

MT Newswires

a year ago

Top Midday Decliners

CNSP

MT Newswires

a year ago

CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
CNSP

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
CNSP

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
CNSP

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
CNSP

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
CNSP

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro
CNSP

CNW Group

a year ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
CNSP

AFP

a year ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
CNSP

Business Insider

a year ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

CNSP

MT Newswires

a year ago

CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week

CNS Pharmaceuticals Announces Reverse Stock Split
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

CNS Pharmaceuticals to Present at Two Investor Conferences in April
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

SaverOne Signs Contract to Install its Systems on 300 Buses of Leading Israeli Transportation Company Bon Tour
CNSP

PR Newswire

a year ago

SaverOne Signs Contract to Install its Systems on 300 Buses of Leading Israeli Transportation Company Bon Tour

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
CNSP

GlobeNewswire

a year ago

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

Fresh Vine Wine, Inc. Signs Definitive Agreement To Acquire Live Entertainment Company Notes Live, Inc.
CNSP

GlobeNewswire

a year ago

Fresh Vine Wine, Inc. Signs Definitive Agreement To Acquire Live Entertainment Company Notes Live, Inc.

Lixiang Education Regains Compliance with Nasdaq Minimum Bid Price Requirement
CNSP

PR Newswire

a year ago

Lixiang Education Regains Compliance with Nasdaq Minimum Bid Price Requirement

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
CNSP

ACCESSWIRE

a year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
CNSP

ACCESSWIRE

a year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
CNSP

PR Newswire

a year ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CNSP

Zacks

a year ago

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Natural Grocers® Now Hiring for New Store in Incline Village, NV
CNSP

PR Newswire

a year ago

Natural Grocers® Now Hiring for New Store in Incline Village, NV

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
CNSP

GlobeNewswire

a year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
CNSP

GlobeNewswire

a year ago

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?
CNSP

Zacks

2 years ago

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
CNSP

Zacks

2 years ago

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

Zedge, Inc. (AMEX:ZDGE) Q1 2024 Earnings Call Transcript
CNSP

Insider Monkey

2 years ago

Zedge, Inc. (AMEX:ZDGE) Q1 2024 Earnings Call Transcript

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
CNSP

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Red Cat Holdings, Inc. Announces Closing of $9.2 Million Public Offering
CNSP

GlobeNewswire

2 years ago

Red Cat Holdings, Inc. Announces Closing of $9.2 Million Public Offering

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
CNSP

ACCESSWIRE

2 years ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Sidoti Events, LLC's Virtual December Small-Cap Conference
CNSP

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
CNSP

Business Wire

2 years ago

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Fresh Vine Wine, Inc. Enters Into Letter of Intent With Live Entertainment and Hospitality Company Notes Live, Inc.
CNSP

GlobeNewswire

2 years ago

Fresh Vine Wine, Inc. Enters Into Letter of Intent With Live Entertainment and Hospitality Company Notes Live, Inc.

Electra Announces Proposed Amendments to Outstanding Warrants
CNSP

Business Wire

2 years ago

Electra Announces Proposed Amendments to Outstanding Warrants

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
CNSP

GlobeNewswire

2 years ago

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

Dario Contracts with New Employer for Cardiometabolic Solution
CNSP

PR Newswire

2 years ago

Dario Contracts with New Employer for Cardiometabolic Solution

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
CNSP

ACCESSWIRE

2 years ago

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
CNSP

GlobeNewswire

2 years ago

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2023
CNSP

Business Wire

2 years ago

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2023

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
CNSP

ACCESSWIRE

2 years ago

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
CNSP

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Allot to Release Third Quarter 2023 Earnings on November 16, 2023 and Reschedules Conference Call to November 22, 2023
CNSP

GlobeNewswire

2 years ago

Allot to Release Third Quarter 2023 Earnings on November 16, 2023 and Reschedules Conference Call to November 22, 2023

Xunlei Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2023
CNSP

GlobeNewswire

2 years ago

Xunlei Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2023

urban-gro, Inc. (NASDAQ:UGRO) Q3 2023 Earnings Call Transcript
CNSP

Insider Monkey

2 years ago

urban-gro, Inc. (NASDAQ:UGRO) Q3 2023 Earnings Call Transcript

AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807
CNSP

ACCESSWIRE

2 years ago

AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807

CNSP

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Spruce Power Holding Corp Earnings Call

Spruce Power Announces Record Revenue in Third Quarter 2023 Earnings Results
CNSP

Business Wire

2 years ago

Spruce Power Announces Record Revenue in Third Quarter 2023 Earnings Results

Profound Medical to Participate in the Stifel 2023 Healthcare Conference
CNSP

GlobeNewswire

2 years ago

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
CNSP

GlobeNewswire

2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Share on Social Networks: